Please login to the form below
Deal Watch table for October 2013
Table listing all the major pharma mergers, acquisitions and collaborations in the past month
This table lists all the major pharma collaborations, acquisitions and mergers agreed during October 2013.
For an indepth analysis of these deals, read 'Pharma deals during October 2013'
| Licensor acquired / licensee acquirer | Deal type | Product / technology | Headline ($m) |
| Celesio / McKesson | Acquisition | Wholesaler and pharmacy chains | 8,300 |
| Mitokyne / Astellas | R&D collaboration and option to acquire | Molecules targeting mitochondrial function to treat genetic, metabolic or neurodegenerative disorders (discovery) | 730 |
| Spirogen / MedImmune | Acquisition | ADC technology - oncology (lead asset in phase II) | 440 |
| Acino / Avista Capital and Nordic Capital | Acquisition | Portfolio of drug delivery products (marketed) | 439 |
| Sideris Pharmaceuticals / Novartis | Option to acquire | Iron chelator SP-420 for transfusional iron overload (preclinical) | 300 |
| *Vivus / Auxilium | Commercialisation | Stendra (avanafil) for erectile dysfunction (approved) | 300 |
| **Epirus / Orygen Biotecnologia | Development, manufacture and commercialisation | Multiple biosimilars including BOW015 (Remicade biosimilar) (phase III) | 275 |
| Depomed / PDL Pharma | Royalty and milestone monetisation | Licence agreements in the type 2 diabetes therapeutic area | 240.5 |
| ImmunoGen / Novartis | Licence | ADC technology - extension of 2010 agreement | 200 |
| ‡Xention / Servier | Development and commercialisation, option to acquire IP after 2 x p2 studies | XEN-D103 ion channel modulator for atrial fibrillation (phase I) | 162.4 |
| Anacor / Valeant | Settlement | Settlement agreement for breach of contract dispute | 143 |
| ‡‡ Stallergenes / Greer Labs | Commercialisation | Oralair, grass allergy sublingual tablet (pre-registration) | 120 |
| Osiris Therapeutics / Mesoblast | Asset acquisition | Mesenchymal stem cell business, including Prochymal (approved) | 100 |
| †Hutchison MediPharma / Eli Lilly | Licence, co-development and commercialisation | ruquintinib VEGF inhibitor for solid tumours (phase II) | 86.5 |
| PharmAkea / Celgene | Strategic three year collaboration, option to acquire company | Discovery platform for small molecules for cancer and fibrotic disease | 35 |
| Moderna Therapeutics / DARPA | R&D grant | mRNA therapeutics for biodefence targets (discovery) | 25 |
| ††Ablynx / Eddingpharm | Licence | Anti-RANKL Nanobody, ALX-0141 for osteoporosis and bone metastases (preclinical) | 2.7 upfront |
All deals are worldwide unless otherwise noted – see below:
* US and Canada
** Brazil
‡ Excluding US and Japan
‡‡ US
† China
†† China, Hong Kong, Macao and Taiwan
ADC = antibody drug conjugate
VEGF = Vascular Endothelial Growth Factor
DARPA = Defense Advanced Research Projects Agency
Subscribe to our email news alerts
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Pfizer reports positive results for elranatamab in multiple myeloma
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- Merck sues US government over Medicare drug price negotiation programme
- European Commission grants two new marketing authorisations for UCB's Bimzelx
- AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants
- Janssen shares positive phase 3 results for cilta-cel in multiple myeloma
- Parkinson’s disease: past, present and future
- How to Increase Engagement During Virtual Events
- AstraZeneca to stop post-marketing study of Andexxa following early success
No results were found
PMHub
Springer Nature
Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...
